Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct;47(4):638-44.
doi: 10.4143/crt.2014.316. Epub 2015 Mar 2.

The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer

Ik-Chan Song  1 , Hyo-Jin Lee  1 , Young-Jun Yang  2 , Yoon-Seok Choi  1 , Hye-Won Ryu  1 , Myung-Won Lee  1 , Ji Young Moon  1 , Deog-Yeon Jo  1 , Samyong Kim  1 , Hwan-Jung Yun  1
Affiliations

The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer

Ik-Chan Song et al. Cancer Res Treat. 2015 Oct.

Abstract

Purpose: There is no regimen that is strongly recommended for more than second-line treatment. We investigated the efficacy and safety of platinum/vinorelbine as more than second-line treatment.

Materials and methods: We selected patients with advanced non-small cell lung cancer (NSCLC) who received treatment with platinum/vinorelbine at Chungnam National University Hospital from August 2001 to December 2013. The primary end point was the response rate, and secondary end points were progression-free survival (PFS), overall survival (OS), and toxicity.

Results: Thirty-five patients were enrolled. Response rate was 22.9% (complete response, 0 patients [0%]; partial response, eight patients [22.9%]; stable disease, 10 patients [28.6%]; progressive disease, 14 patients [40.0%]). A significantly higher response rate was observed for patients who had responded to previous chemotherapy than for those who did not (34.8% [8/23] vs. 0% [0/12], p=0.020). The median PFS was 4 months (range, 1 to 21 months). Patients with adenocarcinoma and non-smokers had a significantly longer PFS than patients with non-adenocarcinoma and smokers (5 months vs. 2 months, p=0.007; 4.5 months vs. 2 months, p=0.046, respectively). The median OS was 10 months (range, 1 to 41 months). Patients with good performance status and non-smokers had a significantly longer OS than patients with poor performance status and smokers (14 months vs. 4 months, p=0.02; 18.5 months vs. 6 months, p=0.049, respectively). The main serious adverse event (grade 3 or 4) was neutropenia (15 events, 13.3%) in a total of 113 cycles.

Conclusion: Platinum/vinorelbine was effective as more than second-line chemotherapy, and the toxicity was tolerable, in patients with advanced NSCLC.

Keywords: Drug therapy; Non-small-cell lung carcinoma; Third-line treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest relevant to this article was not reported.

Figures

Fig. 1.
Fig. 1.
Progression-free survival for patients who received platinum and vinorelbine as more than second-line chemotherapy (n=35).
Fig. 2.
Fig. 2.
Overall survival for patients who received platinum and vinorelbine as more than second-line chemotherapy (n=35).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Asahina H, Sekine I, Horinouchi H, Nokihara H, Yamamoto N, Kubota K, et al. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer. 2012;13:39–43. - PubMed
    1. Girard N, Jacoulet P, Gainet M, Elleuch R, Pernet D, Depierre A, et al. Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice. J Thorac Oncol. 2009;4:1544–9. - PubMed
    1. National Comprehensive Cancer Network . Fort Washington, PA: National Comprehensive Cancer Network; c2015. NCCN clinical practice guidelines in oncology. Non-small cell lung cancer version 3.2014 [Internet] [cited 2014 Nov 3]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. - PubMed
    1. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–103. - PubMed
    1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32. - PubMed

Publication types

MeSH terms

LinkOut - more resources